•  

Directory

Photo of Judy Blumstock
Executive Director, Corporate Development
Work Phone: 647-260-7863

Biographical Info

Judith provides financial strategy and in-depth portfolio reporting for TIAP and its technologies and companies under management. She also takes an active role in fundraising and investor relations, and leads a variety of special projects.

Prior to joining TIAP (previously MaRS Innovation), Judith was a principal with Genesys Capital Partners, one of the largest Canadian-based venture-capital firms focused on the life sciences industry. She is also a past director of Insception, Millenium Biologix Corp., Plexagen Diagnostics, and Zelos Therapeutics Inc. Previously, Judith was a partner with Royal Bank Capital Partners Life Sciences Fund and, prior to that, director of Bio/pharmaceutical Research at Drug Royalty Corporation.

Judith received her M.B.A. in finance from Columbia Business School and her B.Sc. in Biology from the University of Toronto.

Return to top.
Photo of Jasmine Dautovich
Manager, Technology and Venture Development
Work Phone: 647-260-7897

Biographical Info

Jasmine Dautovich supports the life science portfolio at TIAP (previously MaRS Innovation) through evaluation of early-stage technologies by conducting scientific, technical and intellectual property due diligence, assessing market potential and identifying potential industry partners to support new start-up ventures.

Prior to joining TIAP, Jasmine was the Manager of Operations and Clinical Development for a clinical-stage biotechnology company, ScarX Therapeutics, where she was responsible for managing all aspects of technology development through to successful completion of a Phase I clinical trial.

Jasmine holds a M.Sc. in Pharmaceutical Sciences from the University of Toronto and a B.Sc. in Molecular Biology & Genetics from McMaster University.

Return to top.
Photo of Phil Goldbach
Manager, Technology and Venture Development; Manager, Intellectual Property
Work Phone: 647-260-7830

Biographical Info

Phil manages intellectual property (IP) rights across all technologies within TIAP’s (previously MaRS Innovation) portfolio. He advises on various forms of IP protection, assessing patentability and managing patent application filings and prosecution decisions. Phil also manages projects in TIAP’s Life Sciences portfolio. He performs technical and market due diligence on new technologies to support and expand TIAP’s portfolio. In addition, he develops business, technical, and strategic plans and engages with industry partners in order to support new start-up ventures.

Prior to joining TIAP, Phil trained with an intellectual property boutique law firm in downtown Toronto as a member of the firm’s life sciences patent practice group, where he was exposed to a wide array of technologies including biologics, small molecules, medical devices, and information technologies. He has also acted as director of intellectual property for a biotechnology start-up company in Mississauga that specializes in developing antibody-based products for use in animal health and food safety.

Phil holds a PhD in Molecular Genetics from the University of Toronto and a JD from Osgoode Hall Law School.

Return to top.
Photo of Rafi Hofstein
President & CEO
Work Phone: 647-260-7868

Biographical Info

Dr. Raphael (Rafi) Hofstein joined Toronto Innovation Acceleration Partners (previously MaRS Innovation) as President and CEO in June 2009. He is currently member of the board of directors of Life Science Ontario and of Clinical Trials Ontario, as well as a member of the Organizing Committee of the Public Policy Forum on Venture Capital and Innovation (part of the Quebec City Conference) and part of the Ontario Health Innovation Council (OHIC).

Dr. Hofstein received his PhD and Master of Science degrees in Life Sciences and Chemistry from the Weizmann Institute of Science in Rehovot, Israel. His Bachelor of Science degree in Chemistry and Physics is from the Hebrew University in Jerusalem.

Awards he received while completing post-doctoral training and research at the Harvard Medical School in Boston in the Departments of Biological Chemistry and Neurobiology include the Hereditary Disease Foundation Fellowship in 1982-83, and the Chaim Weizmann Postdoctoral Fellowship in 1980-82.

During the 1980s, he held the roles of Scientific Director of Biotechnological Applications Ltd., and Manager R&D and Chief of Immunochemistry at the International Genetic Scientific Partnership, organizations that were pivotal in developing Israel’s world-leading biotechnology sector.

Dr. Hofstein was Scientific Director of the Israeli office of Ecogen Inc., a subsidiary of Monsanto, for over six years before assuming the role of Vice President, Business Development, for Ecogen in Langhorne, Pa.

From 1997 to 1999 Dr. Hofstein was President of Mindsense Biosystems Ltd., an Israeli company that develops neuropsychiatric immune assays, as well as Venture Partner at Medica Venture (a leading VC in Israel). From 1999 to 2009, he held the position of President and CEO of Hadasit Ltd., the technology transfer company of the Hadassah Medical Organization in Jerusalem. 

Dr. Hofstein was the founder and has served as Chair of Hadasit BioHolding Ltd., a publicly-traded holding company (10 start-ups under management) on the Tel Aviv Stock Exchange (TASE) since 2005. Other directorships held on TASE publicly-traded companies include: Bioline RX (drug development); Exalenz (medical devices); and Evogene (agri-bio).

Dr. Hofstein also served as Chair of BIOMED, Israel’s annual biomedical conference, from 2005 to 2007. In addition, Dr. Hofstein is a Co-Founder and Board Member of ILSI, the Israeli Life Science Industry Organization, and a Co-Founder and Executive in Israel’s Tech Transfer Network (ITTN).

Return to top.
Photo of Stacey Ivanchuk
Director, Intellectual Property
Work Phone: 647-260-7867

Biographical Info

Stacey has over 10 years experience relating to intellectual property (IP) protection, management and strategy. She oversees and provides strategic advice for all projects in Toronto Innovation Acceleration’s portfolio spanning diverse technical fields, working closely with the venture development teams to evaluate technologies and develop optimal IP protection strategies. In addition to her IP role, she is responsible for strategic oversight of all technologies originating from Baycrest, a TIAP member.

Prior to TIAP, Stacey was IP manager at Topigen Pharmaceuticals Inc., a Montreal-based biotechnology company (acquired by Pharmaxis Ltd.) where she provided IP-related strategic guidance including portfolio management, budgeting and financial forecasting. She was also formerly IP consultant at Baycrest where she identified and assessed commercial opportunities arising from neurocognitive research. In her role as Scientific Advisor in the IP group of Ogilvy Renault (now Norton Rose Fulbright), she gained experience drafting and prosecuting patent applications, focusing on life sciences/biotechnology patent protection.

Stacey received her B.Sc., Honours (Biology) and M.Sc. in cancer genetics from Queen’s University and her Ph.D. in molecular biology from the University of Toronto.

Return to top.
Photo of Hassan Jaferi
Manager, UTEST
Work Phone: 647-531-4681

Biographical Info

As Manager of UTEST, Hassan works with early-stage startup companies from the University of Toronto and its affiliated hospitals. He helps guide UTEST portfolio companies in the areas of business development, marketing, intellectual property, fundraising and strategy.

Previously, Hassan was a commercialization manager at MaRS Innovation, now Toronto Innovation Acceleration Partners, where he divided his time between projects located in Innovation York and Sunnybrook Health Sciences Centre’s Technology Transfer office, located in the Sunnybrook Research Institute. He conducted due diligence on invention disclosures, aided in patent application preparation and prosecution, executed business development for early-stage technologies and pursued public and private funding to advance early-stage research projects.

Before joining TIAP, Hassan was a commercial development analyst with PARTEQ Innovations, the technology transfer office of Queen’s University, where he managed the commercialization of early-stage technologies and helped managed a start-up company. He has also worked as a patent examiner with the Canadian Intellectual Property Office.

Hassan holds a M.Sc. in space management from the International Space University in Strasbourg, France, and a B.Sc. in computer engineering from the University of Ottawa.

Return to top.
Work Phone: 647 260 7844

Biographical Info

Richard is involved in the scientific due diligence, and assessing the technological development and market potential of projects entering into TIAP’s pipeline. He also scouts for new projects from TIAP’s academic member institutions.

Prior to joining TIAP, Richard conducted market research into colorectal cancer, liquid biopsy technologies and epigenetic technologies, among others, as an intern with the diagnostics startup Enrich Bioscience. His other past experiences include research into the human skin microbiome in the context of psoriatic arthritis at the Krembil Research Institute, and administration of clinical trials in oncology at the Princess Margaret Hospital Cancer Centre.

Richard holds a M.Sc. (Applied) in Biotechnology from McGill University in Montreal and a B.Sc. (Honors) in Molecular Genetics and Neuroscience from the University of Toronto.

Return to top.
Photo of Parimal Nathwani
Vice President
Work Phone: 647-260-7873

Biographical Info

Parimal Nathwani has over 15 years of experience in various aspects of the biotechnology industry including corporate finance, business development, transactions, intellectual property management, technology development and operations. He has been actively involved in forming and managing start-ups, preparing and executing on business plans, raising early-stage capital and in- and out-licensing activities.

Before joining MaRS Innovation, now Toronto Innovation Acceleration Partners (TIAP), Parimal was a healthcare analyst with a boutique investment bank, where he conducted equity research on publicly-traded biotechnology companies in Canada and the U.S. He has also led commercialization activities out of BC Women’s and Children’s Hospital as part of his role at the University of British Columbia’s Industry Liaison Office, and was a research scientist at a start-up biotechnology company involved in drug discovery targeting ABC Transporters.

Parimal received his MBA from Simon Fraser University and his M.Sc. from the University of British Columbia.  He currently sits on the boards of TRIUMF Innovations, Zucara Therapeutics, and Vasomune Therapeutics, and is an observer on the board of Encycle Therapeutics.

Return to top.
Work Phone: 647 260 7853

Biographical Info

Adeola has over 7 years of experience in full-cycle accounting with progressively increasing responsibilities in Financial reporting, Accounts payables and receivables, Financial Analysis, Reconciliations, Budgeting, Financial Controls and Process Improvements.

In his role as Accounting Specialist, New Ventures at TIAP, Adeola conducts the day-to-day accounting and finance activities for several new ventures within TIAP’s portfolio, including Encycle Therapeutics, QD Solar, Vasomune Therapeutics, Bright Angel Therapeutics and Fibrocor Therapeutics. He manages their financial reporting and compliance with GAAP (Generally Accepted Accounting Principles).

Prior to joining TIAP, Adeola was Senior Accounting/Financial Analyst at ProMach Performance Services where he was in charge of month end close process, financial reporting, cash flow forecasting, process improvement and financial controls . He was also actively involved in budgeting and variance analysis and he prepared other financial analysis reports that enabled management decision-making.

Adeola earned his MBA from Morgan State University, Maryland, USA and holds the designation of Chartered Professional Accountant (CPA, CGA Canada). He is also a Fellow (FCCA) of the Association of Chartered Certified Accountant (ACCA Global).

Return to top.
Photo of Susanne Staer
Manager, Corporate Affairs
Work Phone: 647-260-7869

Biographical Info

Susanne is the Corporate Secretary for Toronto Innovation Acceleration Partners (TIAP) (previously MaRS Innovation) and as such is in charge of the integrity of the organization’s governance framework, including compliance with various governing and funding requirements; efficient administration of the Board of Directors and its various governing and advisory committees; and management of the process related to the annual general meetings and accurate record keeping of Board decisions and organizational history.

In addition, Susanne delivers administrative expertise to the executive office, and oversees marketing, external communications, social media and website development. She maintains office efficiency by establishing procedures and standards, and is the point-person for all aspects of the administration of TIAP.

Prior to joining TIAP, Susanne worked closely with to two senior partners in a nation-wide law firm, in the areas of mergers and acquisitions, corporate finance and securities, and general corporate matters. Susanne also trained new administrative staff and was instrumental in setting up various internal intranet functions as they pertained to training and staff administration.

Susanne has an international administrative background through her work in the diplomatic corps under the Ministry of Foreign Affairs of Denmark, through which she was posted to the Royal Danish Embassies in Russia and Ghana.

Return to top.
Photo of Jackie Terry
Executive Assistant to the Vice President
Work Phone: 647-260-7870

Biographical Info

In addition to her responsibilities as EA to the Vice President, Jackie provides administrative support to the boards of several of Toronto Innovation Acceleration Partner’s startup companies.  She also assists with the daily administration of the LAB150 funding initiative for new drug discovery, and is the liaison between TIAP and its partner, Evotec AG, as well as the main contact for the Technology Transfer Offices and researchers at TIAP’s Member institutions who wish to apply to the LAB150 program.

Prior to joining TIAP, Jackie collaborated on and managed projects in the polymer characterization department of an organization that specialized in contract and service-based research, development and testing. Her specialties were innovative techniques for preparing and analyzing materials using various disciplines of microscopy, particularly scanning electron microscopy, mainly in the fields of materials characterization and failure analysis.

Jackie received her B. Sc. in Chemistry from McMaster University in Hamilton, Ontario.

Return to top.
Photo of Julia N. Varela
Analyst, Technology and Venture Development
Work Phone: 647 2607861

Biographical Info

Julia Varela conducts scientific and technical due diligence for projects submitted to TIAP and assesses their commercial potential. She also aids with the scouting of new projects from TIAP’s partner organizations.

Prior to joining TIAP, Julia practised pharmacy at the State Hospital of Sumare (Brazil) and worked as a Quality Assurance intern at Medley-Sanofi where she was responsible for ensuring compliance with GMP guidelines in the manufacturing plant. During her Ph.D., she worked as a Business Development Intern at CDRD where she helped to identify commercial opportunities to aid in the creation of new Canadian healthcare companies.

Julia holds a Ph.D. in Chemical and Biological Engineering from the University of British Columbia in Vancouver, BC; a Graduate Certificate in Science and Technology Commercialisation from Simon Fraser University, Vancouver, BC; a M.Sc. in Biosciences and Technology of Bioactive Products; and a B.Sc. in Pharmacy from the State University of Campinas, Campinas, SP, Brazil.

Return to top.
Photo of Jessica Chutter
Managing Director, Chairman of Biotechnology Investment Banking, Morgan Stanley

Biographical Info

Jessica is the managing director and chairman of Biotechnology Investment Banking at Morgan Stanley. During Jessica’s 30-year career of building Morgan Stanley’s biotechnology franchise, she has been responsible for $30 billion of capital raising and $65B of strategic transactions. In 2017, transactions include leading financings for Axovant, Biohaven, Editas, Galapagos, RegenxBio and Syndax, aggregating $1Bn in proceeds.  Previous strategic transactions include advising Cubist on its $9.5Bn sale to Merck, Pharmasset on its $11Bn sale to Gilead and Elan on its $8.6Bn sale to Perrigo. She has also been involved in the creation of a new asset class involving royalty-backed debt (PhaRMA) where over $16 billion has been raised.

Jessica has a BA in Commerce/Honours Economics from McGill University and an MBA from Harvard Business School.

Return to top.
Photo of Dr. Vivek Goel
PhD, Vice President, Research and Innovation, University of Toronto

Biographical Info

Professor Vivek Goel was appointed Vice President, Research and Innovation of the University of Toronto in December, 2014. Professor Goel is a distinguished scholar with an extensive background in teaching, research and university administration. He obtained his medical degree from McGill University and completed post-graduate medical training in Community Medicine at the University of Toronto. Dr. Goel obtained an M.Sc. in Community Health from U of T and an M.Sc. in Biostatistics from Harvard University’s School of Public Health. His research has focussed on health services evaluation.   He was a founding scientist at the Institute for Clinical Evaluative Sciences (ICES), where he continues as an Adjunct Senior Scientist.

Professor Goel joined the University of Toronto in 1991 as Assistant Professor in the Department of Preventive Medicine and Biostatistics. He was chair of the Department of Health Administration in the Faculty of Medicine from 1999 until 2001, then served as Vice-Provost, Faculty and subsequently was the University’s Vice President and Provost from 2004 until 2008. He was founding President and CEO of Public Health Ontario from 2008 until 2014, where he was highly successful in building an academic public health services agency that provided scientific and technical advice to front-line practitioners. Prior to rejoining U of T he served as Chief Academic Strategist with Coursera, a global platform that connects universities and learners with online courses.

Return to top.
Photo of Angus J. Grant PhD
Corporate Vice President, Business Development, Celgene Corporation

Biographical Info

Angus Grant joined Celgene as Vice President North American Regulatory Affairs in 2006, in the Summit NJ Headquarters.  In 2008, Angus moved to London as Head of Europe RA for 3 years. Angus returned to the Summit NJ Headquarters as VP, Business Development and Global Alliances, in 2011, where he has since completed multiple innovative deals and has in tandem built the Alliance Management function, which now manages over 50 collaborations and investments with pharmaceutical and biotech partners.

Prior to joining Celgene, Angus held positions as Executive Director for Alliance Management for Novartis Oncology, and positions of increasing responsibility in Regulatory Affairs for Merck KGaA/EMD, Rhone-Poulenc Rorer, and SmithKline Beecham Pharmaceuticals.  Prior to working in industry, Angus served as a Senior Staff  Fellow at the U.S. Food and Drug Administration Center for Biologics, and conducted his post-doctoral research in immunotherapy at the National Cancer Institute. Angus received his Ph.D. in Anatomy & Immunology from the Medical College of Virginia.

Return to top.
Photo of Laurie Harrison
Vice President, CFOThe Hospital for Sick Children

Biographical Info

Ms. Harrison has 30 years of experience in Ontario healthcare organizations providing strategic and operational leadership in Finance, Business Development, Treasury, Strategic Planning, Human Resources, and Operations

Ms. Harrison has a BSc degree in Business Administration from the University of Tennessee as well as an MBA from Northwestern (Kellogg) and York Universities.  She holds the Certified Public Accountant designation.  She sits on the boards of several health related enterprises.

As a healthcare executive, Ms. Harrison has a proven track record of operating within complex organizations and bringing the needs of multiple constituents to establish a clear vision for the future.

Return to top.
Photo of Grace Lee Reynolds
Chief Business Officer & Secretary-Treasurer, MaRS Discovery District

Biographical Info

Grace Lee Reynolds oversees the operations portfolio, which includes real estate & events, data & technology, finance, legal, and corporate development functions at MaRS. She is also responsible for governance and financial strategy and accountability, and serves as the Secretary-Treasurer of the Board. Committed to organizations that drive meaningful social impact, she has held leadership roles in healthcare and charitable organizations. Prior to joining MaRS in 2011, she worked at University Health Network, where she was Director, Finance in the Corporate Office, Toronto General & Western Hospital Foundation and Toronto Western Hospital. She began her career at Ernst & Young before moving to the Research Institute of The Hospital for Sick Children, followed by the SickKids Foundation, where she was Senior Director, Finance. Grace is a Chartered Professional Accountant and holds Bachelor of Arts and Master of Accounting degrees from the University of Waterloo.

Return to top.
Photo of Mario Piccinin
MBA, CPA, CA – Partner, Ernst & Young LLP

Biographical Info

Mario is an Audit Partner and the Greater Toronto Area Life Science Leader at EY with 26 years of experience providing audit and business advisory services to private and public companies in a variety of industries.

His practice is focused on Life Science companies including Healthcare, Diagnostic, Med Tech, Pharma and Biotechnology companies.

Mario has had extensive hands on experience working with companies in all aspects of their life cycles, from start-up to mature organizations, helping them achieve their goals.

Professional Affiliations

Treasurer of Life Sciences Ontario

Board Member of St. Joseph’s Health Centre

Education

Chartered Accountant, Ontario

Bachelor of Business Administration, York University (1988)

Masters of Business Administration, York University (1989)

Return to top.
Photo of Dr. Laszlo Radvanyi
President & Scientific DirectorOntario Institute for Cancer Research (OICR)

Biographical Info

Dr. Laszlo Radvanyi brings a strong oncology research background in academia as well as leadership experience in international pharma and biotech, making him an ideal leader for OICR. Laszlo was educated at the University of Toronto, earning a PhD in Clinical Biochemistry in 1996. Laszlo joined OICR from EMD Serono (Merck KGaA, Darmstadt, Germany), where he was Senior Vice President Global Head of the Immuno-Oncology (IO) Translational Innovation Platform (TIP) and Senior Scientific Advisor for Immunology and IO. While at EMD Serono, Laszlo rebuilt and re-organized its IO research platform, hiring key talent, and re-focused and rejuvenated the IO R&D pipeline. He also established key academic alliances focusing on biomarker-driven clinical trials. At EMD Serono, Laszlo also played a role in an alliance with Pfizer developing anti-PD-L1 (avelumab) and co-led EMD Serono’s CAR T-cell program in partnership with Intrexon and Ziopharm. Prior to joining EMD Serono, Laszlo was a Professor in the Department of Melanoma Medical Oncology at the University of Texas, MD Anderson Cancer Center in Houston for 10 years. While at MD Anderson, he established a GMP-grade T-cell therapy manufacturing program for metastatic melanoma using expanded tumour-infiltrating lymphocytes (TIL) and performed basic research on TIL biology and effector function. In recognition of his research accomplishments, he was awarded an MD Anderson Division of Cancer Medicine Research Award. Laszlo also has small biotech experience and was founding CSO for Iovance Therapeutics, commercializing T-cell therapies for melanoma and other cancers. He designed and built the biotech’s R&D facility in Tampa, Florida and led research and development activities leading to two IND submissions. He also has 7 patents in the cancer immunotherapy and cell therapy field. Among his other current activities, Laszlo is on the Keystone Conferences Scientific Advisory Board, is an Associate Editor for the Journal of Immunotherapy for Cancer (JITC), and has served on grant review panels for numerous national and international agencies.

Return to top.
Photo of Dr. Bradly G. Wouters
Executive Vice President, Science & ResearchUniveristy Health Network (UHN)

Biographical Info

Dr. Bradly Wouters is an internationally recognized leader and cancer researcher. He became Executive Vice President of Science and Research at UHN in 2016 and prior to that served as the Interim Director of Research at the Princess Margaret Cancer Centre since 2014. He joined UHN in 2008 as Senior Scientist and Director of the Princess Margaret Hypoxia Program, and has held faculty appointments at the University of Toronto in the Department of Medical Biophysics and the Department of Radiation Oncology since that time. Prior to joining UHN, Dr. Wouters was Professor and Head of Experimental Radiation Oncology at Maastricht University in the Netherlands. As EVP of Science and Research, Dr. Wouters is focused on creating an environment that incentivizes, facilitates and rewards excellence in basic, translational and clinical research across all elements of UHN.

Return to top.
Photo of Dr. Catherine Zahn
President & CEOCentre for Addiction and Mental Health (CAMH)

Biographical Info

Dr. Zahn was appointed President and CEO of the Centre for Addiction and Mental Health (CAMH) in 2009.  CAMH is Canada’s leading mental health hospital and the country’s largest academic health science centre focused on mental illness.

She received her MD (honours) from the Faculty of Medicine at the University of Toronto (U of T), where she completed her residency training in neurology.  She holds an MSc in Health Administration from U or T and has completed the Directors’ Education Program at the U of T Rotman School of Management.  Dr. Zahn is a Professor in the U of T Faculty of Medicine and a Fellow of the Royal College of Physicians and Surgeons of Canada.  She has made numerous contributions to health care in Ontario through her leadership in hospital integration, technology assessment and mental healthcare system improvement.

Recent honours include membership in the Order of Canada, Doctor of Laws degrees (honoris causa) from Western University, (London, Ontario) and Ryerson University, (Toronto, Ontario) and the Bryden Award for Outstanding Achievement (York University). The International Association of Business Communicators has also named her Communicator of the Year. Dr. Zahn serves on a number of health-care related boards and committees, as well as on the Board of Governors of Upper Canada College.

Dr. Zahn is a champion for the integration of psychiatry and neuroscience, passionately working to steer mental illness into the mainstream of healthcare, promoting equitable access to healthcare resources for people with mental illness.

Return to top.
Photo of Mike Rhodin
(Retired) Senior Vice President of IBM; Founder of the Watson Group

Biographical Info

Mike Rhodin recently retired from IBM after 33 years,  and 7 years as a corporate officer.  Most recently he was responsible for founding the IBM Watson business units.  Prior to that,  Mike founded IBM’s solution units around their Smarter Planet initiatives including Smarter Cities,  Smarter Commerce and Smarter Analytics.  During the last financial crisis,  Mike was based in Zurich, Switzerland and responsible for most of IBM’s European operations.

Mike received a Bachelor of Science (Computer Science) degree from University of Michigan in 1984,  and was recognized with an Alumni Merit Award in 2016.  He was also recognized with an honorary Doctor of Science degree from Roanoke College for his contributions to the development of artificial intelligence systems.

Mr. Rhodin began his professional career in 1984 where he joined IBM as software engineer.  He held various technology and management roles until 1997 when he moved to corporate headquarters and started his executive management career.

He is a member Supervisory Board for TomTom,  based in Amsterdam,  a leader in telematics,  HD mapping technologies and consumer navigation devices.  Mike also serves as an Independent Director for HZO, a waterproofing technology provider for the IOT devices, where he chairs both the Intellectual Property and Compensation committees.  He is also a member of the International Advisory Board for Group Santander,  one of the worlds leading financial services organizations,  as well as on the Advisory Board for Arboretum Ventures,  and Ann Arbor based venture capital company focused on the healthcare market.

Mike also serves as a member of the National Advisory Board for the University of Michigan Computer Science program.  He has also served as a Director in the Partnership for New York City,  a not for profit board focused on economic development,  as well as Jobs For Massachusetts,  a similar not for profit in the Boston area.

Return to top.
Photo of Dr. Andy J. Smith
President & CEO, Sunnybrook Health Sciences Centre
Return to top.